Core Insights - Fortrea has been recognized as a "Leader" in pharmacovigilance operations by Everest Group in its annual Pharmacovigilance Operations PEAK Matrix Assessment 2025, highlighting its strong position in both pre-and post-approval PV operations [1][2] Company Overview - Fortrea is a leading global contract research organization (CRO) that provides clinical development solutions to the life sciences industry, partnering with biopharmaceutical, biotechnology, medical device, and diagnostic companies [4] - The company offers end-to-end safety solutions that cover the entire product lifecycle, from early clinical phases to post-approval [2][3] Industry Context - The pharmacovigilance landscape is evolving with increased therapeutic complexity, regulatory scrutiny, and patient safety expectations, prompting sponsors to seek service providers that offer integrated scientific insights and strategic support [3] - Fortrea's dual-strength capabilities in clinical-stage safety services and robust post-marketing operations distinguish it in the market, supported by a global Qualified Person Responsible for Pharmacovigilance (QPPV) and technology-led innovations [3] Assessment Details - The Everest Group report evaluated 29 PV operations providers, assessing their service focus, solution offerings, and domain investments through a comprehensive RFI process and client reference checks [2] - Fortrea's strengths in scientific depth, scalability, and global reach have been consistently recognized by clients, contributing to its leadership position in the assessment [3]

Core Insights - Tech Mahindra has launched an autonomous pharmacovigilance solution utilizing NVIDIA AI software to improve drug safety management [1][3] - The solution aims to address industry challenges such as manual delays and data overload by enhancing the accuracy, speed, and efficiency of pharmacovigilance processes [1][3] Technology and Framework - The solution is powered by Tech Mahindra's TENO framework, which integrates NVIDIA's AI technology to automate and optimize pharmacovigilance workflows [2][4] - It incorporates NVIDIA AI Enterprise software, including NVIDIA NeMo™, NVIDIA NIM™ microservices, and NVIDIA AI Blueprints, to streamline various processes such as case intake and compliance management [2][4] Operational Benefits - The AI-driven solution can autonomously handle case classification, prioritization, and verification of pharmacovigilance emails, significantly reducing human error [2][3] - It processes over 1,000 daily cases of adverse drug reactions (ADR) and can reduce turnaround times by up to 40%, enhance data accuracy by 30%, and cut operational costs by 25% [3][4] Industry Impact - The collaboration between Tech Mahindra and NVIDIA aims to revolutionize drug safety management by transforming pharmacovigilance from a reactive to a predictive approach [3][4] - The integration of AI enhances the ability to monitor medicines throughout their lifecycle, supporting better identification of potential safety issues [4]